Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
VolitionRx Limited (NYSE AMERICAN: VNRX) Will Have
Our Full Focus This Morning
—Thursday, September 17, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Closer Look At (VNRX) While It’s Still Early… September 17, 2026 Dear Reader, Less than 90 minutes remain before the opening bell, and VolitionRx Limited (NYSE AMERICAN: VNRX) is one name we’re keeping a close eye on. Clinical progress, partnership activity, and a tightly held float are all converging at once. Something is happening in the diagnostics sector that caught our eye. The science of epigenetics — the study of how genes are expressed and regulated, rather than the DNA sequence itself — has been generating peer-reviewed clinical results at a rate suggesting a real inflection point may be forming. And one company sitting right at the center of that shift is VolitionRx Limited (NYSE AMERICAN: VNRX). What makes (VNRX) worth watching right now isn't a single headline. It's the convergence of several threads — published clinical validation in one of the world's top critical care journals, a multi-platform technology suite spanning cancer detection and sepsis, active licensing discussions with more than a dozen global diagnostic leaders, and a combined addressable market the company estimates at more than $27B across all of its product pillars, per an August corporate update. That's a lot of runway for a company with a market cap of less than $10M, according to Zacks Small-Cap Research… And it may explain why the analyst consensus still carries a bullish momentum rating across five covering firms, with targets reaching as high as $24 from Jones. The disconnect between current valuation and the scale of what's in motion here is hard to ignore. VolitionRx Limited (NYSE AMERICAN: VNRX) is topping our watchlist this morning—Thursday, September 17, 2026. 
But it’s important to know, (NYSE AMERICAN: VNRX) has a float less than 13M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. The Science Behind the Signal
At its core, Volition has built a proprietary platform called Nu.Q® that detects and measures nucleosomes — the structural units that package DNA inside every cell — circulating in the bloodstream. When disease disrupts normal cell function, epigenetic changes show up in those circulating nucleosomes. That's the foundational concept… But the execution across three distinct technology pillars is where things start to get interesting for anyone paying attention to (VNRX). The company's most advanced commercial asset is Nu.Q® NETs — a CE-marked sepsis detection assay already available in European hospitals through a multi-year relationship with Revvity's automated IDS i10 platform. Revvity co-markets the Nu.Q® NETs kits to hospitals across Europe, with the product already reaching dozens of hospital sites — meaning this isn't a theoretical commercial relationship but an active one. Then there's Capture-Seq™ — a method for multi-cancer early detection that has generated some of the most striking data in the company's pipeline… In September, Dr. Andrew Retter presented at the ESMO MAP conference in London, demonstrating that the Capture-Seq™ method detected 49 of 49 cancers in one cohort — including 23 early-stage cases — with zero false positives among 21 healthy controls. A separate blinded validation cohort of 81 subjects showed 95% sensitivity for Stage I and II cancers. Those numbers matter because the underlying method physically removes 99.7% of background DNA, resulting in a 180-fold enrichment of the target signal — a novel approach that could potentially make cancer detection from a routine blood draw more accessible and cost-effective than existing liquid biopsy methods… If validated in larger studies, Capture-Seq™ could address a combined early detection and minimal residual disease market the company estimates at roughly $36B, per the ESMO MAP announcement. And the third pillar — Nu.Q® Vet — is already generating revenue with a canine cancer screening test available in more than 20 countries, per a recent corporate update. A feline lymphoma version detecting 86% of cancers at 97% specificity could potentially double the addressable companion animal market, according to the same update. Three pillars, three distinct markets, and a growing body of published evidence behind each one. Clinical Validation That Commands Attention
What elevates (VNRX) above a purely early-stage profile is the weight of clinical evidence now stacking up behind its lead assets. A peer-reviewed paper published in Critical Care Medicine — one of the most respected journals in intensive care — analyzed 971 patients across 33 ICUs in Germany and concluded that elevated H3.1 nucleosome levels at admission are independently associated with 28-day mortality and acute kidney injury requiring renal replacement therapy… Every log-10 jump in baseline H3.1 concentration raised the 28-day risk of needing renal replacement therapy by 80%, per the Zacks SCR report. The journal also published an accompanying editorial asking whether H3.1 nucleosomes represent a biomarker, a mechanism, or both — a clear signal that the medical community is treating this technology with genuine seriousness. And that 971-patient data set isn't the only one backing the science. Volition's Nu.Q® NETs summary, compiled in July 2026, references multiple large-scale studies including a 1,713-patient MARS cohort and an 832-participant U.S. multi-center study — building a body of evidence that could accelerate regulatory and commercial conversations. Beyond the lab, the company has demonstrated a lateral flow finger-prick test for Nu.Q® NETs that correlates with centralized laboratory results, according to the August corporate update — the same filing that outlined $27B+ in combined addressable markets across the company's three technology pillars. 
That matters because a bedside test delivering results in minutes instead of hours — similar to COVID-era rapid tests — could dramatically expand the addressable market for sepsis detection into emergency rooms, ICUs, and even home settings… With an estimated 166M sepsis cases worldwide, the potential reach is enormous. And a Mayo Clinic collaboration has extended Nu.Q® NETs into trauma care, with a pilot study of 639 patients showing sharply elevated nucleosome levels in trauma patients who developed venous thromboembolism. Volition is now supplying the Mayo Clinic with an automated analyzer to help develop a trauma patient model — another pathway that could further widen the Nu.Q® NETs footprint. What Could Move the Needle From Here
Several potential catalysts sit on the near-term horizon for VolitionRx Limited (NYSE AMERICAN: VNRX)… The French government-backed DETECSEPS program — a ~$7.3M real-world evaluation of early sepsis detection — is using Nu.Q® NETs as the sole biomarker and was on track to begin recruitment in the fall of 2026. In France, the company is also pursuing a reimbursement dossier for its Nu.Q® Lung Cancer test, supported by the Hospices Civils de Lyon — one of Europe's leading cancer centers. If approved within the typical five-month timeframe, management anticipates the test could enter routine clinical use by the end of 2026 and advance toward broader adoption in 2027, per the Zacks report — that would mark the first real-world clinical deployment of a Nu.Q® assay for cancer patients, and a gateway for potential rollout to additional countries. On the partnership front, (VNRX) announced a collaboration with Sysmex Corporation — a multi-B market cap global leader in hemostasis diagnostics listed on the Tokyo Exchange — with the Nu.Q® NETs assay already transferred onto Sysmex's platform and optimization underway. That's the company's third human licensing arrangement, joining existing deals with Werfen for antiphospholipid syndrome and a co-marketing agreement with Hologic for Nu.Q® Discover services… And the pipeline of discussions runs deeper still — management has confirmed active negotiations with more than twelve additional diagnostics and liquid biopsy companies across all three technology pillars. On September 14, Volition prepaid the outstanding balance on its $7.5M Lind senior secured convertible note — more than eight months ahead of schedule — reducing equity overhang. CEO Cameron Reynolds stated the company is executing against its plan to strengthen its financial footing, with operating expenses already 32% lower year-over-year in the second quarter and first-half revenue of $1.4M representing a 112% jump over the same period last year, per the corporate momentum update. 7 Reasons Why We’re Taking A Closer Look At (VNRX) This Morning—Thursday, September 17, 2026…
1. Small-Float: With less than 13M shares listed as available to the public,VNRX’s small float could witness the potential for big moves if demand begins to shift. 2. Capture-Seq™ Cancer Detection Data: The platform detected 49 of 49 cancers in one cohort with zero false positives and showed 95% sensitivity for Stage I/II cancers in a separate blinded validation — data presented at the ESMO MAP conference in London. 3. Peer-Reviewed Sepsis Validation: A 971-patient study published in Critical Care Medicine independently confirmed that Nu.Q® NETs H3.1 is associated with mortality and kidney injury in sepsis — accompanied by an editorial in the same journal. 4. $27B+ Combined Addressable Market: The company estimates its total addressable market across all pillars — Capture-Seq™, Nu.Q® NETs, and Nu.Q® Vet — at more than $27B on an annualized basis. 5. Growing Partnership Pipeline: Active discussions with more than twelve global diagnostic and liquid biopsy companies, including a new collaboration with Sysmex Corporation alongside existing arrangements with Werfen and Hologic. 6. $5M Veterinary Milestone Approaching: A feline lymphoma clinical manuscript has been submitted for peer review, and publication is expected to unlock a $5M contractual payment from Antech/Heska. 7. Analyst Coverage: Across five covering analysts, the consensus carries a bullish momentum rating with targets reaching as high as $24 from JonesTrading — while Zacks Small-Cap Research assigns a DCF-based valuation of $2.11 per share. Take A Closer Look At (VNRX) While It’s Still Early…
The epigenetics space is at a point where clinical data, commercial partnerships, and regulatory milestones are starting to converge for (VNRX) in a way that could make the coming quarters worth watching closely. The pieces are moving… If the DETECSEPS program delivers results, if the feline manuscript publishes on schedule, and if even one or two of those dozen-plus licensing discussions close — the story for VolitionRx Limited (NYSE AMERICAN: VNRX) could shift quickly. For a profile with a market cap under $10M eyeing a $27B+ combined addressable market, the gap between where this company sits today and where it could be headed may deserve your attention. Take a closer look at (VNRX) while it’s still early. Also, our next update could be hitting very shortly, keep an eye out for it. Sincerely, Jeff Ackerman Managing Editor Stock News Trends |
No comments:
Post a Comment